Prioritization of Molecular Targets for Antimalarial Drug Discovery
Name
acsinfecdis.1c00322.pdf
Description
Published version
Size
2.63 MB
Format
Adobe PDF
Checksum (MD5)
960f3b3b89af76e208429125c9c8387a
Author(s)
Forte, Barbara
Ottilie, Sabine
Plater, Andrew
Campo, Brice
Dechering, Koen J
Gamo, Francisco Javier
Goldberg, Daniel E
Istvan, Eva S
Lee, Marcus
Lukens, Amanda K
Date Issued
2021
Journal
ACS Infectious Diseases
Publisher
American Chemical Society (ACS)
Citation
Forte, Barbara, Ottilie, Sabine, Plater, Andrew, Campo, Brice, Dechering, Koen J et al. 2021. "Prioritization of Molecular Targets for Antimalarial Drug Discovery." ACS Infectious Diseases, 7 (10).
Version
Final published version
Abstract
There is a shift in antimalarial drug discovery from phenotypic screening toward target-based approaches, as more potential drug targets are being validated in Plasmodium species. Given the high attrition rate and high cost of drug discovery, it is important to select the targets most likely to deliver progressible drug candidates. In this paper, we describe the criteria that we consider important for selecting targets for antimalarial drug discovery. We describe the analysis of a number of drug targets in the Malaria Drug Accelerator (MalDA) pipeline, which has allowed us to prioritize targets that are ready to enter the drug discovery process. This selection process has also highlighted where additional data are required to inform target progression or deprioritization of other targets. Finally, we comment on how additional drug targets may be identified.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1021/ACSINFECDIS.1C00322
